Literature DB >> 12163044

Chemokine receptor CCR5: polymorphism at protein level.

Shunji Suzuki1, Tomoko Miyagi, Linda F Chuang, Peter M Yau, Roy H Doi, Ronald Y Chuang.   

Abstract

Polymorphisms in chemokine receptor CCR5 genes have been implicated in HIV disease progression, resistance, or non-progressive infection. Multiple CCR5 transcripts and mRNA diversity have also been identified. This study presents evidence to show that two distinct forms of CCR5 protein, 62 and 42k Da, are present in human lymphocytic cells and monkey peripheral blood mononuclear cells. The ratio of these two forms of CCR5 changes with cell growth. The 62k Da CCR5 predominates if the electrophoresis sample buffer does not contain reducing agent. However, the 62 and the 42 kDa CCR5 are not interconvertible. Morphine sulfate induces the formation and expression of both forms of CCR5 whereas RANTES, MIP-1alpha or MIP-1beta inhibits them. Localization studies indicate that the 62 kDa CCR5 resides mainly on the cell membrane and the 42 kDa CCR5 is present solely in the cytoplasm of the cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163044     DOI: 10.1016/s0006-291x(02)00908-7

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Distribution of CCR-5Δ32, CCR2-64I, and SDF-1-3'A alleles among Jordanians.

Authors:  Omar F Khabour; Laila J Abu-Haweleh; Karem H Alzoubi
Journal:  AIDS Res Hum Retroviruses       Date:  2012-07-31       Impact factor: 2.205

Review 2.  Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.

Authors:  Hager Mohamed; Theodore Gurrola; Rachel Berman; Mackenzie Collins; Ilker K Sariyer; Michael R Nonnemacher; Brian Wigdahl
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

Review 3.  Structure and function of the HIV envelope glycoprotein as entry mediator, vaccine immunogen, and target for inhibitors.

Authors:  Ponraj Prabakaran; Antony S Dimitrov; Timothy R Fouts; Dimiter S Dimitrov
Journal:  Adv Pharmacol       Date:  2007
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.